BONUS CAP-ZERTIFIKAT - ROCHE GS Stock

Certificat

DE000VM4A0N4

Market Closed - Deutsche Boerse AG 13:40:13 2024-05-31 EDT
292.9 EUR +0.47% Intraday chart for BONUS CAP-ZERTIFIKAT - ROCHE GS
1 month+6.44%
3 months+4.55%
Date Price Change
24-05-31 292.9 +0.47%
24-05-30 291.5 +0.97%
24-05-29 288.7 +0.86%
24-05-28 286.3 -0.43%
24-05-27 287.5 -0.05%

Delayed Quote Deutsche Boerse AG

Last update May 31, 2024 at 01:40 pm

More quotes

Static data

Product typeBonus- and Part-Guarantee-Certificates
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer Vontobel Vontobel
WKN VM4A0N
ISINDE000VM4A0N4
Date issued 2023-10-23
Strike 300 CHF
Maturity 2024-09-20 (110 Days)
Parity 1 : 1
Emission price 278.6
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 303.2
Lowest since issue 260.5
Spread 6.59
Spread %2.19%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
231 CHF
Average target price
277.5 CHF
Spread / Average Target
+20.14%
Consensus